5 results about "Mifepristone" patented technology

The invention discloses a Yao medicine composition with effects of regulating menstruation and stopping bleeding as well as a preparation method and application of the Yao medicine composition, and belongs to the technical field of ethnic medicines. The composition is prepared from paris polyphylla, radix zanthoxyli, giantleaf ardisia rhizome, ovateleaf holly bark, radix fici simplicissimae and callicarpa macrophylla. The preparation method comprises the following steps: carrying out secondary water extraction on the raw materials, concentrating to specified density, standing, precipitating, removing impurities, preparing and the like. The Yao medicine composition disclosed by the invention not only has a remarkable hemostatic effect, but also has an excellent endocrine regulation function. Pharmacodynamic experiments show that in a rat dysfunctional blood model induced by combination of mifepristone and misoprostol, the composition can significantly reduce the bleeding amount and shorten the bleeding time, the hemostatic effect is equivalent to that of a positive control drug, namely Gongxuening capsule and a pure paris polyphylla extract, and although a paris polyphylla preparation exists, the hemostatic effect of the composition is remarkably improved. However, the problem that a single paris polyphylla preparation is weak in FSH / LH regulation capacity is solved, and data prove that the compound is irreplaceable.

The present application relates to the use and combination of Shenghua Xinggao and mifepristone in treating embryo residue after medical abortion. The use of Shenghua Xinggao and mifepristone in treating embryo residue after medical abortion can make the blood flow signal of residue disappear and HCG decrease rapidly, thereby greatly reducing the risk of surgical curettage for patients, and has important clinical value.

The present invention relates to the use of the compound mifepristone or a pharmaceutically acceptable salt, solvate or active metabolite thereof at a low dose in the treatment and / or prevention of endometriosis associated pain.

The invention discloses a rodent sterilant synergist and application of the rodent sterilant synergist in preparation of sterilant bait. According to the invention, ketoconazole with relatively strong CYP enzyme inhibitory activity is taken as a synergist and is compounded with mifepristone and baits to form the compound sterilant for harmful rats. Wherein ketoconazole can effectively inhibit the activity of CYP enzyme, significantly reduce the metabolic clearance rate of mifepristone, improve the oral bioavailability of mifepristone, maintain the same sterility prevention and control effect, greatly reduce the use dosage of the sterilant, and realize reduction and synergy. The compound pest sterilant provided by the invention solves the problems of poor killing effect, short lasting effect, fast rebound, high cost, easy generation of drug resistance and accidental killing of natural enemies and non-target organisms in the existing single use of a steroid hormone sterilant, and provides a new solution for sustainable control of pest.

Safe and effective methods for treating a subject suffering from cortisol excess of and in need of concomitant administration of mifepristone along with a CYP3A4 inducer are disclosed herein. The CYP3A4 inducer may be, for example, mitotane, rifampin (also known as rifampicin), rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, or St. John's wort. In embodiments, the CYP3A4 inducer is a strong CYP3A4 inducer. In embodiments, the CYP3A4 inducer is a moderate CYP3A4 inducer. In embodiments, the CYP3A4 inducer may be any CYP3A4 inducer. Mifepristone may be orally administered. Mifepristone may be administered with food.